Deposits of beta amyloid protein in the brain are a common sign of Alzheimer’s disease. AMYPAD will study the value of using positron emission tomography (PET) imaging to scan people’s brains for beta amyloid deposits. AMYPAD will carry out beta amyloid PET imaging on an unprecedented number of people who are suspected to be in the early stages of Alzheimer’s disease. The goal is to determine the clinical added value of PET imaging in diagnosis and patient monitoring, and to develop data to establish its usefulness in clinical trials. AMYPAD will work closely with IMI’s EPAD project, which is working to increase our understanding of the early stages of dementia and creating a platform to test treatments designed to prevent dementia.
AMYPAD
Amyloid imaging to prevent Alzheimer’s disease
FACTS & FIGURES
| Start Date |
|
| End Date |
|
| Call |
IMI2 - Call 5
|
| Grant agreement number |
115952
|
Type of Action:
RIA (Research and Innovation Action)
| Contributions | € |
|---|---|
| IMI Funding |
11 999 886
|
| EFPIA in kind |
12 233 950
|
| Other |
3 095 452
|
| Total Cost | 27 329 288 |
Summary
Participants Show participants on map
EFPIA companies
- GE Healthcare Ltd, Little Chalfont, United Kingdom
- Janssen Pharmaceutica NV, Beerse, Belgium
- Piramal Imaging Ltd, Havant, United Kingdom
Universities, research organisations, public bodies, non-profit groups
- Alzheimer Europe, Luxembourg, Luxembourg
- Barcelonabeta Brain Research Center Foundation, Barcelona, Spain
- Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France
- Karolinska Institutet, Stockholm, Sweden
- STICHTING VUmc, Amsterdam, Netherlands
- Stichting Katholieke Universiteit / Radboud university medical center, Nijmegen, Netherlands
- University College London, London, United Kingdom
- University Hospital of Cologne, Cologne, Germany
- University of Edinburgh, Edinburgh, United Kingdom
- Université de Genève, Genève 4, Switzerland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- IXICO Technologies Ltd, London, United Kingdom
- Synapse Research Management Partners S.L, Barcelona, Spain
| Participants | |
|---|---|
| Name | IMI funding in € |
| Alzheimer Europe | 200 500 |
| Barcelonabeta Brain Research Center Foundation | 1 089 000 |
| Centre Hospitalier Universitaire De Toulouse | 558 000 |
| IXICO Technologies Ltd | 1 001 136 |
| Karolinska Institutet | 650 250 |
| Stichting Katholieke Universiteit / Radboud university medical center | 175 000 |
| STICHTING VUmc | 5 408 000 |
| Synapse Research Management Partners S.L | 557 750 |
| University College London | 934 500 |
| University Hospital of Cologne | 650 250 |
| University of Edinburgh | 775 500 |
| Total Cost | 11 999 886 |
CONTACT
Project coordinator
Frederik Barkhof
Stichting VUmc
Netherlands
+31 629 554 626
f.barkhof[at]vumc.nl
Frederik Barkhof
Stichting VUmc
Netherlands
+31 629 554 626
f.barkhof[at]vumc.nl
Project contact
info[at]amypad.org
info[at]amypad.org
LINKS AND DOCUMENTS
Project website
amypad.eu